Summary of the recommendations by the EURL-ECVAM Scientific Advisory Committee (ESAC) on the Scientific Validity of Replacements for Animal-Derived Antibodies. Presented at the ICCVAM Communities of Practice Webinar 2020, "Use of Animal-free Affinity Reagents", January 2020.
The lecture describes the performance and presentation of the antibiograms by the hospitals based upon recommendations of CLSI and shows experience of some of our MOH hospitals with the advantages and pitfalls in them.
The lecture describes the performance and presentation of the antibiograms by the hospitals based upon recommendations of CLSI and shows experience of some of our MOH hospitals with the advantages and pitfalls in them.
Process development considerations for quality and safety of vaccinesDr. Priyabrata Pattnaik
"New Technologies Symposium" presentation at Annual General Meeting of Developing Country Vaccine Manufacturers Network (DCVMN), 5th-7th October 2015, Bangkok, Thailand.
Vaccine Cell Bank and Virus Seed CharacterizationMilliporeSigma
In this webinar, you will learn:
- about the importance of characterising cell banks and virus seed stocks in order to meet worldwide regulatory requirements.
- the difference between guidance documents from different organizations worldwide
- new technologies for determining the identity of cell substrates and virus seed stocks
- detecting adventitious agent contamination
Automation in microbiology, changing concept and defeating challengesAyman Allam
A presentation about the automation in microbiology presented in 24th conference of the Egyptian Society of Medical Microbiology and immunology, 4/2017.
GVK Biosciences (GVK BIO) offers screening services for drug discovery to determine biological activity and properties customized to meet the research needs of the Pharma and Biotech industries. Our range of assays include Biochemical, Cellular, ADME assays & Animal models for profiling of NCEs for Potency, Selectivity, Efficacy, Drugability and Toxicity.
detect and identify common human bacterial pathogens in high purity water.Saad Farooqi
A rapid culture independent methodology toquantitatively detect and identify common human bacterial pathogens associated with contaminated high purity water
Automated system for bacterial identificationDEEKSHANT KUMAR
[DOWNLOAD IT OPEN IT WITH MICROSOFT POWERPOINT THEN YOU WILL BE ABLE TO UNDERSTAND THE TOPIC COVERED.]
1. WHOLE TEXT IS RELIABLE.
2. TEXT HAS BEEN TAKEN FROM STANDARD TEXT BOOK FOR MEDICAL MICROBIOLOGY.
3. SOME PICTURE HAS BEEN TAKEN FROM JOURNAL.
It has been developed for the detection, enumeration & identification of bacteria & yeasts in clinical specimens.
It is an instrument used for automatic computer-assisted identification of bacteria
It mainly involves staining, motility test, cultural characteristics, a series of biochemical tests.
The automatic bacteria identification system automatically identifies the bacteria in very short time.
This slideshow was created by April Finnen of Dynport Vaccine Company LLC of Frederick, Maryland and was shared with me for the purposes of my column on Examiner.com.
Improving Immunohistochemistry Standardization in your Laboratory: Renewable ...Candy Smellie
What is the impact of assay failure in your laboratory and how do you monitor for it?
To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.
Process development considerations for quality and safety of vaccinesDr. Priyabrata Pattnaik
"New Technologies Symposium" presentation at Annual General Meeting of Developing Country Vaccine Manufacturers Network (DCVMN), 5th-7th October 2015, Bangkok, Thailand.
Vaccine Cell Bank and Virus Seed CharacterizationMilliporeSigma
In this webinar, you will learn:
- about the importance of characterising cell banks and virus seed stocks in order to meet worldwide regulatory requirements.
- the difference between guidance documents from different organizations worldwide
- new technologies for determining the identity of cell substrates and virus seed stocks
- detecting adventitious agent contamination
Automation in microbiology, changing concept and defeating challengesAyman Allam
A presentation about the automation in microbiology presented in 24th conference of the Egyptian Society of Medical Microbiology and immunology, 4/2017.
GVK Biosciences (GVK BIO) offers screening services for drug discovery to determine biological activity and properties customized to meet the research needs of the Pharma and Biotech industries. Our range of assays include Biochemical, Cellular, ADME assays & Animal models for profiling of NCEs for Potency, Selectivity, Efficacy, Drugability and Toxicity.
detect and identify common human bacterial pathogens in high purity water.Saad Farooqi
A rapid culture independent methodology toquantitatively detect and identify common human bacterial pathogens associated with contaminated high purity water
Automated system for bacterial identificationDEEKSHANT KUMAR
[DOWNLOAD IT OPEN IT WITH MICROSOFT POWERPOINT THEN YOU WILL BE ABLE TO UNDERSTAND THE TOPIC COVERED.]
1. WHOLE TEXT IS RELIABLE.
2. TEXT HAS BEEN TAKEN FROM STANDARD TEXT BOOK FOR MEDICAL MICROBIOLOGY.
3. SOME PICTURE HAS BEEN TAKEN FROM JOURNAL.
It has been developed for the detection, enumeration & identification of bacteria & yeasts in clinical specimens.
It is an instrument used for automatic computer-assisted identification of bacteria
It mainly involves staining, motility test, cultural characteristics, a series of biochemical tests.
The automatic bacteria identification system automatically identifies the bacteria in very short time.
This slideshow was created by April Finnen of Dynport Vaccine Company LLC of Frederick, Maryland and was shared with me for the purposes of my column on Examiner.com.
Improving Immunohistochemistry Standardization in your Laboratory: Renewable ...Candy Smellie
What is the impact of assay failure in your laboratory and how do you monitor for it?
To develop genetically defined IHC Reference Standards with consistent protein expression levels for analytic validation and quantitative assessment of immunohistochemistry assays.
Buffalo Biolabs (BBL) CRO capabilities, March 2014Sphere Software
Buffalo Biolabs (BBL) is a science-intensive Biotech company conducting preclinical contract research in a boutique fashion while solving intricate scientific problems, primarily in the field of cancer treatment, diagnostics and prevention; additional focus – infectious diseases.
General principle of immunoassay Theoretical basis and optimization of immun...Ashish Gadage
Unlock the mysteries of immunoassays with this comprehensive PowerPoint presentation. Delve into the fundamental principles that underpin immunoassay techniques, exploring the theoretical foundations and key concepts. From antigen-antibody interactions to signal amplification strategies, this presentation provides valuable insights into the world of immunoassay science.
Key Topics:
Basics of Immunoassay: Antigen-Antibody Interactions
Types of Immunoassays: ELISA, Western Blot, and More
Signal Detection and Amplification Techniques
Factors Affecting Assay Sensitivity and Specificity
Optimization Strategies for Enhanced Performance
Emerging Trends in Immunoassay Technology
Who Should View:
Designed for scientists, researchers, and students in the fields of immunology, biochemistry, and medical diagnostics. Whether you're new to immunoassays or seeking advanced insights, this presentation caters to a broad audience.
Presenter: Mr. Gadage Ashish Rambhau
(M Pharm Pharmacology)
Pravara Rural Education Society pravaranagar,Loni .
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
“Immunogenicity testing of Biotechnology Products and the Impact to Biosimilars”
Illustrates procedures and potential outcomes of immunogenicity testing for biotherapeutics
Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan. Hóa mô miễn dịch và các câu hỏi liên quan.
What is greenhouse gasses and how many gasses are there to affect the Earth.moosaasad1975
What are greenhouse gasses how they affect the earth and its environment what is the future of the environment and earth how the weather and the climate effects.
hematic appreciation test is a psychological assessment tool used to measure an individual's appreciation and understanding of specific themes or topics. This test helps to evaluate an individual's ability to connect different ideas and concepts within a given theme, as well as their overall comprehension and interpretation skills. The results of the test can provide valuable insights into an individual's cognitive abilities, creativity, and critical thinking skills
ISI 2024: Application Form (Extended), Exam Date (Out), EligibilitySciAstra
The Indian Statistical Institute (ISI) has extended its application deadline for 2024 admissions to April 2. Known for its excellence in statistics and related fields, ISI offers a range of programs from Bachelor's to Junior Research Fellowships. The admission test is scheduled for May 12, 2024. Eligibility varies by program, generally requiring a background in Mathematics and English for undergraduate courses and specific degrees for postgraduate and research positions. Application fees are ₹1500 for male general category applicants and ₹1000 for females. Applications are open to Indian and OCI candidates.
DERIVATION OF MODIFIED BERNOULLI EQUATION WITH VISCOUS EFFECTS AND TERMINAL V...Wasswaderrick3
In this book, we use conservation of energy techniques on a fluid element to derive the Modified Bernoulli equation of flow with viscous or friction effects. We derive the general equation of flow/ velocity and then from this we derive the Pouiselle flow equation, the transition flow equation and the turbulent flow equation. In the situations where there are no viscous effects , the equation reduces to the Bernoulli equation. From experimental results, we are able to include other terms in the Bernoulli equation. We also look at cases where pressure gradients exist. We use the Modified Bernoulli equation to derive equations of flow rate for pipes of different cross sectional areas connected together. We also extend our techniques of energy conservation to a sphere falling in a viscous medium under the effect of gravity. We demonstrate Stokes equation of terminal velocity and turbulent flow equation. We look at a way of calculating the time taken for a body to fall in a viscous medium. We also look at the general equation of terminal velocity.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...University of Maribor
Slides from:
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Track: Artificial Intelligence
https://www.etran.rs/2024/en/home-english/
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Studia Poinsotiana
I Introduction
II Subalternation and Theology
III Theology and Dogmatic Declarations
IV The Mixed Principles of Theology
V Virtual Revelation: The Unity of Theology
VI Theology as a Natural Science
VII Theology’s Certitude
VIII Conclusion
Notes
Bibliography
All the contents are fully attributable to the author, Doctor Victor Salas. Should you wish to get this text republished, get in touch with the author or the editorial committee of the Studia Poinsotiana. Insofar as possible, we will be happy to broker your contact.
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...Travis Hills MN
Travis Hills of Minnesota developed a method to convert waste into high-value dry fertilizer, significantly enriching soil quality. By providing farmers with a valuable resource derived from waste, Travis Hills helps enhance farm profitability while promoting environmental stewardship. Travis Hills' sustainable practices lead to cost savings and increased revenue for farmers by improving resource efficiency and reducing waste.
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptxRASHMI M G
Abnormal or anomalous secondary growth in plants. It defines secondary growth as an increase in plant girth due to vascular cambium or cork cambium. Anomalous secondary growth does not follow the normal pattern of a single vascular cambium producing xylem internally and phloem externally.
Phenomics assisted breeding in crop improvementIshaGoswami9
As the population is increasing and will reach about 9 billion upto 2050. Also due to climate change, it is difficult to meet the food requirement of such a large population. Facing the challenges presented by resource shortages, climate
change, and increasing global population, crop yield and quality need to be improved in a sustainable way over the coming decades. Genetic improvement by breeding is the best way to increase crop productivity. With the rapid progression of functional
genomics, an increasing number of crop genomes have been sequenced and dozens of genes influencing key agronomic traits have been identified. However, current genome sequence information has not been adequately exploited for understanding
the complex characteristics of multiple gene, owing to a lack of crop phenotypic data. Efficient, automatic, and accurate technologies and platforms that can capture phenotypic data that can
be linked to genomics information for crop improvement at all growth stages have become as important as genotyping. Thus,
high-throughput phenotyping has become the major bottleneck restricting crop breeding. Plant phenomics has been defined as the high-throughput, accurate acquisition and analysis of multi-dimensional phenotypes
during crop growing stages at the organism level, including the cell, tissue, organ, individual plant, plot, and field levels. With the rapid development of novel sensors, imaging technology,
and analysis methods, numerous infrastructure platforms have been developed for phenotyping.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
20240520 Planning a Circuit Simulator in JavaScript.pptx
Scientific Validity of Replacements for Animal-Derived Antibodies
1. Rebecca Clewell
21st Century Tox Consulting
21 January 2020
Scientific Validity of Replacements for
Animal-Derived Antibodies
2. ESAC review of the scientific validity of replacements for
animal-derived antibodies
Working Group meeting on 8-9 November 2018
Opinion endorsed on 3-5 June 2019
ESAC Core members: Rebecca Clewell (Chair); Carl Westmoreland
ESAC Ad-hoc members: Carl Borrebaeck; Andrew Bradbury; Stefan Dübel; Alison Gray;
Achim Knappik; Andreas Plückthun
ECVAM: Joao Barroso, Marlies Halder
Expertise covering…
• Antibody generation with
animal and non-animal
technologies
• Antibody engineering
• Antibody use in many
research applications
including diagnostics,
therapeutics and research
• Academia and industry
3. Charge question
Review the available proof of the scientific validity of antibodies
and non-antibody affinity reagents, used in research,
diagnostics and regulatory applications, generated using
animal-free technologies
4. Definitions
Animal-derived antibodies – Produced using methods where animal immunization is required.
• Includes monoclonal and polyclonal antibodies, and immunized recombinant
methods.
Nonanimal-derived antibodies – Immunglobulin antibodies derived from in vitro systems without
the use animal immunization at any phase of production.
Non-antibody affinity reagents – Non‐immunoglobulin scaffolds including aptamers and affimers.
May use peptide or oligonucleotide scaffolds.
Recombinant technologies - Recombinant technologies may be used in the production of both
animal and non-animal derived antibodies. This term encompasses a wide range of techniques
that includes libraries from immunized animals and hybridomas.
5. Phage display: the technology that revolutionised
animal-free antibody production
7. Recombinant antibody formats
(A) (B) Full-length IgG antibody where
V=variable,C=constant, H=heavy, L=light,
F=fragment, ab=antibody binding. Disulfide bonds
are dark yellow. (C) Bivalent F(ab’)2
(D) Monovalent Fab.
(E) Single-domain VHH antibody.
(F) Single-chain fragment variable (scFv).
(G) scFv-Fc are scFvs dimerized by the Fc domain.
(H) Fab-A is with the fusion of alkaline phosphatase,
that can be directly detected using a colorimetric
substrate and is an example of a wide variety of tags
that can be directly fused to the antibody fragment,
pre- or post-selection.
8. Principles of action
The design of a non-animal derived antibody universal phage display library
and selection of binders adopts the same mechanistic principles of nature that
have been relied upon to produce animal derived antibodies thereby
mimicking and surpassing the whole animal immune response through the
careful control of in vitro parameters.
These include:
combinatorial diversification,
selection of antibody-antigen binding partners, and
affinity maturation for improved specificity.
9. Current applications for nonanimal-derived
antibodies - research
• Research Applications
• ELISA (sandwich)
• Western blotting
• IHC
• Flow cytometry
• IP / Pull-down
• Multiplexed assays /
Arrays
• Microfluidic assays
• In vitro diagnostics
• ELISA (sandwich, competition, direct,
indirect, homogeneous)
• Calibrators and controls
• Lateral flow
• Immunohematology, e.g. blood typing
• Multiplexed assays
• Biopharma analysis
• PK and immunogenicity testing
• Environmental monitoring, security
• Food testing
10. Case studies with nonanimal derived antibodies
• Non-animal derived antibodies in clinical use
• 20/125 human or humanized antibodies in Phase II, III or approved, are human antibodies
derived from phage display (Jain et al., 2017)
• hClat
• EU project to demonstrate feasibility of generating the large number of antibodies
• Publications showing favorable comparison to traditional technologies
• Non-animal derived antibodies are successfully used in diagnostic applications
• Catalogue antibodies exist and are similar in price to traditional antibodies
11. Scope of the Working Group Report
With the goal of supporting current research and diagnostic applications, the working group
focused on non-animal derived antibodies, as they:
are relatively mature technologies,
have large bodies of evidence supporting their utility,
have been used in broad ranging applications, and
have few perceived hurdles to rapid implementation (e.g., cost, patents).
It was noted, however, that there would be value in convening a separate working group to review
non-antibody affinity reagents as replacements for animal-derived antibodies.
12. Advantages of nonanimal-derived antibodies
• Control over affinity selection conditions (e.g. selection under defined biochemical
conditions selects only antibodies that are functional at these conditions)
• Free choice of detection system (e.g. fusion to tags, enzymes, etc.)
• Non-animal-derived antibodies are sequence-defined:
– Polyclonals not sequence-defined
– Hybridomas only sequence-defined with substantial effort
• Duplicate antibody with identical binding and specificity profiles easily reconstituted
• Unlimited reproducibility of scientific results:
– Reproducibility of antibodies over time and across labs
– No batch-to-batch variation
– No irretrievable loss of clone
13. Misconceptions about limitations of nonanimal-derived
antibodies
• Perceptions that non-animal-derived antibodies have low affinity due to wrongly
comparing avidity of animal-derived antibodies to monovalent affinity of non-animal-
derived antibodies
– After selection, non-animal-derived antibodies similar to rat and mouse monoclonal affinity
– After affinity maturation, non-animal-derived antibodies similar to rabbit monoclonal affinity
• Few providers perceived as lack of utility, but actually more related to cost/demand
(majority focused on therapeutic applications)
• Some of the same limitations as conventional antibodies
– Antigen specific difficulties: carbohydrates, complex biological samples, etc.
– These limitations represent areas that have not been fully explored, not necessarily impossibilities
14. ESAC Opinion
1. Non-animal-derived antibodies are mature reagents generated by a
proven technology
• No general or systematic disadvantages with respect to affinity, stability/shelf
life and specificity
• Used in approved therapeutic & diagnostic applications
• Available from catalogues as research reagents and generated as commercial
service
• Thousands of non-animal-derived affinity reagents generated in EU- & NIH-
funded programs
15. ESAC Opinion
2. Non-animal-derived antibodies offer significant additional scientific
benefits
• Knowledge of the sequence provides a unique identifier as well as
unlimited and sustainable supply, which will improve experimental
reproducibility
• Phage display technology allows the guided selection of essential
properties, such as specificity, compatibility to certain assay conditions,
cross-reactivities, stability or affinity
16. ESAC unanimous conclusion
The experts conclude on the scientific evidence that non-animal-
derived antibodies are able to replace animal derived antibodies in the
vast majority of applications. Moreover, well-characterised,
recombinant affinity reagents will improve the reproducibility of science
and positively impact society
17. EURL ECVAM recommendations
• Awareness raising and dissemination of information: availability, cost, scientific benefits
• Education and training: webinars, e-learning, hands-on training courses
• Project authorisation: use of animals to generate antibodies should systematically be challenged
by authorising bodies
• Review of publicly and privately funded projects: in the interest of ethical standards and quality of
science, all funding applications should detail any newly generated antibody, and these should be
non-animal-derived
• Provision of funding to fully characterise affinity reagents generated in EU- (and US NIH)-funded
programs
• Manufacturers/suppliers should replace the animal-derived antibodies available in their
catalogues by non-animal derived affinity reagents.
• Academic institutions should co-ordinate efforts to establish non-animal-derived universal
recombinant libraries for their research activities